Objective To explore the mutations of EGFR， Runx3， Met in non-small-cell lung carcinoma patients and their correlation with pathological classification， TNM stage and survival period.Methods A total of 96 fresh tumor specimens were collected from June 2014 to February 2016 through surgical procedures. The expressions of EGFR， Runx3 and Met were detected by immunohistochemistry， and the mutations of EGFR， Runx3 and Met genes in tissue samples were detected by next generation sequencing (NGS) to study the correlation of EGFR， Runx3 and Met expression， mutation status with pathological classification， TNM stage and survival period in NSCLC patients. The patients were follow-up by telephone or outpatient service. The follow-up time will be from the diagnosis of the case to December 31， 2019.Results Runx3 expression was related to TNM stage， recurrence and Metastasis (P<0.05). Met expression was related to stage and histological typing (P<0.05).EGFR mutation is related to patient’s gender， smoking history， histological classification and survival time (P<0.05). Runx3 mutation was related to patient age， histological classification， stage， recurrence and metastasis， survival time (P<0.05). The EGFR and Runx3 mutation have the positive correlation with the survival time. The expression and mutation of Runx3 have the positive correlation with the recurrence and metastasis. In contrast， the patient’s age， gender， smoking history， histological classification， stage， recurrence and metastasis， survival time， and pathological differentiation were not related to the Met mutation (P>0.05).Conclusion EGFR mutations can coexist with Runx3 and Met mutations， and the Met mutation rate is low. The mutations of EGFR and Runx3 are expected to become potential indicators for histological typing and prognosis of NSCLC patients， and provide theoretical support for the implementation of precise treatment.